other material
confidence high
sentiment positive
materiality 0.60
Coherus sets LOQTORZI price at $8,892.03/vial for NPC treatment
Coherus Oncology, Inc.
- FDA approved LOQTORZI (toripalimab-tpzi) on Oct 27 for first-line and later-line metastatic NPC.
- Coherus announced wholesale acquisition cost of $8,892.03 per single-use vial on Nov 27.
- LOQTORZI is co-administered with cisplatin and gemcitabine in first-line setting.
- This pricing establishes commercial launch basis for the PD-1 inhibitor in NPC.